Reneo Pharmaceuticals (RPHM) - Bathi resik saben saham (EPS TTM)

Reneo Pharmaceuticals (RPHM) effectively terminated its previous research due to failures in final testing, resorting to a merger to salvage its assets. GURU.Markets data is displayed on this chart, where the fundamental EPS TTM metric reflects current trends, and the indicator value reaches -1.70. The company is currently focusing on developing treatments for rare mitochondrial pathologies. Such orphan medicine is entirely non-cyclical and maximally resilient to macroeconomic shocks.
Rincian metrik komprehensif lan analitis Reneo Pharma (RPHM)

Annual net earnings per share reflects the actual portion of income attributable to a single security. By analyzing the trend of the rolling annual EPS, an investor determines the fundamental value of the asset without market noise. The metric is calculated as the ratio of final profit to the number of shares, remaining sensitive to one-off transactions. Historical extremes help avoid buying at the peak. The stability of this indicator for Reneo Pharmaceuticals (RPHM) is supported by the optimization of chemical compound supplies, which eliminates downtime in drug development.